Abstract:Abstract Background The microtubule‐associated protein tau is implicated in the development of a class of diverse neurodegenerative disorders, referred to as tauopathies, with symptoms of dementia and parkinsonism. Tauopathies comprise more than 20 clinicopathological entities, including Alzheimer’s disease, which accounts for 70% of dementia cases worldwide. In combination with clinical diagnosis and neuropathology, the reconstruction of different tau filaments by cryogenic electron microscopy (cryo‐EM) further points to the presence of distinct tau folds. The knowledge of these disease‐specific aggregate conformers provides a platform for the establishment of novel diagnostic methods and more tailored therapeutic approaches. Method In order to investigate this problem, this project aims to selectively amplify tau in vitro from human brain homogenates affected by Alzheimer’s disease (AD) and Pick’s diseases (PiD). Kinetic analysis for drug discovery for the specific process of tau aggregation that takes place in Alzheimer’s disease was performed. Result Strain discrimination was achieved, with a significant acceleration relative to the off‐target control, suggesting formation of two different fibril structures. Cryo‐EM was performed to confirm whether the in vitro AD‐like tau aggregates resembled those extracted from brains.We identify specific tau aggregation inhibitors, through in silico docking to binding sites on the surface of the cryo‐EM structure of tau fibrils adopting an AD fold. Conclusion The application of this line of research is illustrated by a study of the aggregation kinetics of AD‐like tau fibrils, and of its potential in drug discovery. In perspective, the approach that we present offer novel opportunities for the systematic in vitro study of the tau aggregation process as it may happen in the human brain. References (WHO), W. H. O. et al. (2019). Dementia fact sheet. Alzheimer’s disease facts and figures. Alzheimer’s and Dementia 18 , 700‐789 (2022). Chia, S. et al. Structure‐Based Discovery of Small‐Molecule Inhibitors of the Autocatalytic Proliferation of alpha‐Synuclein Aggregates. Mol Pharm (2022).

Protocol for the isolation and proteomic analysis of pathological tau-seeds

Experimental and Computational Protocols for Studies of Cross-Seeding Amyloid Assemblies.

In Vitro Amplification of Pathogenic Tau Seeds from Neurodegenerative Disease Patient Brains

Alzheimer proteopathic tau seeds are biochemically a forme fruste of mature paired helical filaments

Tau seeding without tauopathy

Seeding Activity-Based Detection Uncovers the Different Release Mechanisms of Seed-Competent Tau Versus Inert Tau via Lysosomal Exocytosis

Modeling Tauopathy Using Human-Like Pathogenic Tau Seeds.

In Vitro Amplification of Pathogenic Tau Conserves Disease-Specific Bioactive Characteristics

Sensitive detection and propagation of brain-derived tau assemblies in HEK293 based wild-type tau seeding assays

Aqueous extractable nonfibrillar and sarkosyl extractable fibrillar Alzheimer's disease tau seeds have distinct properties

In situ seeding assay: A novel technique for direct tissue localization of bioactive tau

Exosomal and vesicle-free tau seeds-propagation and convergence in endolysosomal permeabilization

A seeding based cellular assay of tauopathy

Quantitative profiling of posttranslational modifications of pathological tau via sarkosyl fractionation and mass spectrometry

Tau Seeds Are Subject to Aberrant Modifications Resulting in Distinct Signatures.

Correction To: Anatomic Survey of Seeding in Alzheimer's Disease Brains Reveals Unexpected Patterns.

Novel Peptidomic Approach for Identification of Low and High Molecular Weight Tauopathy Peptides Following Calpain Digestion, and Primary Culture Neurotoxic Challenges

Tau seeding and spreading in vivo is supported by both AD-derived fibrillar and oligomeric tau

F2-06-01: MAJOR DIFFERENCES BETWEEN THE SELF-ASSEMBLY, SEEDING BEHAVIOR, AND INTERACTION WITH MODULATORS OF HEPARIN-INDUCED VERSUS IN-VITRO PHOSPHORYLATED TAU

Seeding activity of skin misfolded tau as a biomarker for tauopathies

A brain‐seeded fibril amplification models the aggregation process of tau in Alzheimer’s disease for drug discovery